Русский / English
Enter the query
News
Press Center
phone: +7 495 785 29 07
fax: +7 499 230 32 94
press@interros.ru
Contacts
06.08.2018
In July 2018, Petrovax Pharm received Marketing Authorization No. LP-004951 for Grippol® Quadrivalent, a 4-valent inactivated subunit adjuvanted vaccine designed for prevention of influenza. It is the most advanced flu vaccine in the world that employs an antigen sparing technology and has a high preventive activity and safety.
More Topics Petrovax Pharm
16.07.2018
The event took place within the framework of the educational project «We and Media». Participants of the round table discussed ways of fighting dangerous infectious diseases and the role of the media in the popularization of the vaccine prophylaxis.
More Topics Petrovax Pharm / vaccine prophylaxis / quadrivalent vaccine
19.06.2018
Andrey Bougrov, Senior Vice President of MMC Norilsk Nickel and board member of the RSPP, chaired a joint meeting of the RSPP’s Committee on Corporate Relations and the National Council on Corporate Governance (NSKU) Working Group on Improving Corporate Law. Participants discussed the draft bill «On Amendments to the Federal Law ‘On Countering the Illegal Use of Insider Information and Market Manipulation and on Amending Certain Legislative Acts of the Russian Federation’.»
More Topics Russian Union of Industrialists and Entrepreneurs / RSPP / RUIE
27.11.2017
At the sixth annual Russian Pharma Awards 2017, Polyoxidonium, a Russian combination product that is an immunomodulator, detoxifier, and antioxidant, took the prize for «Product of choice for treating and preventing acute viral respiratory infection in children».
More Topics Petrovax Pharm
10.10.2017
Boehringer Ingelheim has concluded phase one of their localization effort aimed at manufacturing their innovative thrombolytic medicines in Russia: the first batches of Metalyse (tenectaplase) for acute heart attack treatment were produced at NPO Petrovax Pharm facilities.
More Topics Petrovax Pharm